drug
amivantamab
Marketedupdated 6mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5indications
investigational
NSCLC
all catalysts(11)
approval · 11
May 21, 2021
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Dec 21, 2021
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 4, 2022
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Mar 1, 2024
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Aug 19, 2024
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Sep 19, 2024
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Feb 14, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Aug 14, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Sep 3, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Oct 8, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 7, 2025
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Trials studying amivantamab
- phase1A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
- phase2A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- phase1A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
- phase3A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- phase3A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
- phase2Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
- phase3A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- phase3A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
News(10)
- J&J’s Rybrevant nets FDA approval in head and neck cancerThe FDA has granted accelerated approval to Johnson & Johnson’s cancer shot Rybrevant in head and neck cancer that’s come back after previous chemotherapy and immunotherapy. The approval is the fir…endpoints · 12d ago
- FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaThe U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and n…fda_press · 13d ago
- ArriVent collapses on disappointing lung cancer dataMore than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.biopharma_dive · 1mo ago
- ArriVent’s phase 3 lung cancer trial flops, sinking stockA phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading on the Nasdaq.fiercebiotech · 1mo ago
- Rare EGFR mutation increases lung cancer risk 62 times in never smokersA rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.fiercebiotech · 2mo ago
- Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefitAnalysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…biospace · 2mo ago
- Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerCullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…fiercebiotech · 2mo ago
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 3mo ago
- Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionTaiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.biospace · 3mo ago
- Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestTaiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…endpoints · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that